Publications by authors named "A Mykietiuk"
Introduction: After the implementation of mitigation strategies during the COVID-19 pandemic, the incidence of respiratory viruses, including human coronaviruses (HCoV), experienced a significant decrease. The aim of this study is to characterize the epidemiology and clinical aspects of HCoV infections in ambulatory adults during COVID-19 pandemic times.
Methods: descriptive, prospective, longitudinal study performed in a private hospital in La Plata, Buenos Aires, Argentina between November 2020 and October 2022; 458 outpatient adults with upper respiratory tract infections (URTI) were studied undergoing clinical and microbiological follow-up.
Introduction: During the SARS-CoV-2 pandemic, Argentina population suffered from significant changes in population mobility due to non-pharmaceutical interventions. The aim of this study was to describe the impact of the mobility restrictions to the rates of positivity and diversity among different respiratory viruses.
Methods: Retrospective analytical study performed at Instituto Médico Platense in La Plata that included 458 patients with nasopharyngeal swab to search for respiratory pathogens by multiplex PCR.
Introduction: Clinical features and outcomes of SARSCoV-2 infections may change between different waves of the pandemic. The objective of this study was to compare clinical characteristics and outcomes between two cohorts of patients hospitalized for COVID-19 during the first and second waves in Argentina.
Methods: Multicenter and prospective registry of patients =18 years old with a confirmed diagnosis of COVID-19 admitted to 18 hospitals in Argentina during the first wave (March to October 2020) and second wave (March to July 2021) of the pandemic.
Importance: Immune dysregulation contributes to poorer outcomes in COVID-19.
Objective: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia.
Design, Setting, And Participants: Randomized, double-masked, placebo-controlled clinical trial using a master protocol to investigate immunomodulators added to standard care for treatment of participants hospitalized with COVID-19 pneumonia.
Article Synopsis
- - The INSIGHT 006 trial tested Flu-IVIG, an antibody treatment, showing beneficial outcomes for patients with influenza B but not for those with influenza A.
- - Analysis of patient sera revealed that specific antibody types and their ability to bind to Fcγ receptors played a role in treatment effectiveness, with positive outcomes linked to higher FcγR-binding antibodies in influenza B patients.
- - The study emphasizes the importance of understanding antibody functionalities in improving treatments for influenza, indicating that targeted therapies could enhance patient outcomes, particularly for influenza B infections.